Larotrectinib Bayer

DRUG3 trials

Sponsors

Bayer Consumer Care AG, Bayer AG, Nationwide Childrens Hospital, Nationwide Childrens Hospital

Conditions

Newly diagnosed high grade glioma (HGG) including diffuse intrinsic pontine glioma (DIPG)Solid tumors harboring NTRK fusion

Phase 1

(20290) A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors

Active, not recruitingCTIS2022-502668-20-00

Bayer Consumer Care AG, Bayer AGSolid tumors harboring NTRK fusion

Start: 2017-04-11Target: 73Updated: 2025-03-20

Phase 2

(20289) A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors

CompletedCTIS2022-502667-38-00

Bayer Consumer Care AG, Bayer AGSolid tumors harboring NTRK fusion

Start: 2016-06-20End: 2025-09-29Target: 41Updated: 2025-06-05

A Pilot and Surgical Study of Larotrectinib for Treatment of Children with Newly Diagnosed High-Grade Glioma with NTRK Fusion

RecruitingCTIS2023-508953-16-00

Nationwide Childrens Hospital, Nationwide Childrens HospitalNewly diagnosed high grade glioma (HGG) including diffuse intrinsic pontine glioma (DIPG)

Start: 2024-10-25Target: 5Updated: 2024-12-12